Latest Breaking News On - Trisalu trinav - Page 1 : comparemela.com

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery.

United statesTrisalu trinavStevenc katzCenters for medicare medicaid servicesUniversity of texas md anderson cancer centerSociety of interventional radiology annual scientific meetingCurrent medical researchTrisalus life sciencesSociety of interventional radiologyInterventional radiology annual scientificPressure enabled drug deliveryTrisalus infusion systemHypovascular solidCancer centerInterventional radiologyMedicaid services

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Developmen

– New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier presentation from pancreatic adenocarcinoma trial –– Median Progression-Free Survival was 1.

United statesStevenc katzSapna patelTrisalu trinavExchange commissionSociety of immunotherapyUniversity of texas md anderson cancer centerTrisalus life sciencesMedian progression free survivalDisease control rateTrisalus lifeInfusion systemProgression free survivalChief medical officerPressure enabled regional immuno oncologyPressure enabled drug delivery

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

– New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal.

United statesStevenc katzTrisalu trinavSapna patelExchange commissionUniversity of texas md anderson cancer centerTrisalus life sciencesSociety of immunotherapyTrisalus lifeInfusion systemProgression free survivalDisease control rateChief medical officerPressure enabled regional immuno oncologyPressure enabled drug deliveryPancreatic retrograde venous infusion system

TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

– New data from PERIO-03 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of a TLR9 agonist in pancreatic tumors – .

United statesTrisalu trinavMichaels leeStevenc katzTrisalus life sciencesExchange commissionSociety of immunotherapyUniversity of texas md anderson cancer centerPressure enabled drug deliveryTrisalus infusion systemMedical oncologyChief medical officerPressure enabled regional immuno oncologyInfusion systemSalus life sciencesPancreatic retrograde venous infusion system

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting
wsiltv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wsiltv.com Daily Mail and Mail on Sunday newspapers.

United statesKamaneh montazeriJoele frankWilkinson brimmer katcherAaron palash allison sobelStevenc katzTrisalu trinavMedtech acquisition corporationExchange commissionAmerican society of clinical oncologyStock exchangeTrisalus life sciencesMedtech acquisition corporation nasdaqSalus life sciencesBusiness combinationAmerican society